Key Developments: Cambrex Corp (CBM.N)

CBM.N on New York Stock Exchange

14.39USD
4:01pm EDT
Price Change (% chg)

$-0.26 (-1.77%)
Prev Close
$14.65
Open
$14.50
Day's High
$14.60
Day's Low
$13.64
Volume
115,057
Avg. Vol
40,074
52-wk High
$15.62
52-wk Low
$8.85

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cambrex Corp Reaffirms FY 2103 Guidance
7:02am EDT 

Cambrex Corp announced that for fiscal 2013, it expects sales, excluding the impact of foreign currency, to increase between 8% and 12% over 2012, and EBITDA to be between $62 and $68 million, an increase of 8% to 18% over 2012. The Company reported revenue of $273 million in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $301 million for fiscal 2013.  Full Article

Cambrex Corp Reaffirms FY 2013 Guidance
Friday, 3 May 2013 07:00am EDT 

Cambrex Corp announced that for fiscal 2013, it expects sales, excluding the impact of foreign currency, to increase between 8% and 12% over 2012, and EBITDA to be between $62 and $68 million, an increase of 8% to 18% over 2012. The Company reported revenue of $273 million in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $305 million for fiscal 2013.  Full Article

Cambrex Corp And Dow Chemical Co Collaborate To Manufacture Drug-Solubility Solution
Thursday, 14 Feb 2013 09:30am EST 

Cambrex Corp and Dow Chemical Co announced that they have executed an agreement for Cambrex to contract manufacture Dow Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement. This is the final step in building on the solubilization partnership that Dow and Bend Research announced in October 2012 and it will help Dow to commercially supply solubility enabling excipients. Construction has already begun on the new operational facility at Cambrex Karlskoga with commercial product availability set for year-end 2013. Dow's polymer science and application expertise, coupled with Cambrex's capabilities positions Dow for rapid entry into the market.  Full Article

Cambrex Corp Comments On FY 2013 Revenue Guidance; Issues FY 2013 EBITDA Guidance
Wednesday, 6 Feb 2013 05:05pm EST 

Cambrex Corp announced that for fiscal 2013, it expects sales, excluding the impact of foreign currency, to increase between 8% and 12% over 2012, and EBITDA to be between $62 and $68 million, an increase of 8% to 18% over 2012.  Full Article

Cambrex Corp Reaffirms FY 2012 Guidance
Monday, 5 Nov 2012 04:15pm EST 

Cambrex Corporation announced that it is reaffirming sales and EBITDA guidance for fiscal 2012 and expects sales, excluding the impact of foreign currency, will increase between 10% and 13% versus 2011, and that fiscal 2012 EBITDA will be between $54 and $58 million. EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities. For fiscal 2012, the Company continues to expect Zenara to have revenues in the low single digit millions and a small EBITDA loss. The Company reported revenue of $256 million in fiscal 2011. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $275 million for fiscal 2012.  Full Article

Cambrex Corp Announces New Supply Agreement
Tuesday, 14 Aug 2012 04:21pm EDT 

Cambrex Corp announced that it has entered into an agreement to supply an active pharmaceutical ingredient for a customer's Phase 3 program during 2013 and 2014. Under this non-exclusive supply arrangement, Cambrex will manufacture and deliver Phase 3 and pre-launch quantities of this product candidate. This agreement is expected to contribute over $20 million to 2013 revenues and potentially more in 2014 depending on regulatory developments, the timing of completion of Cambrex's capacity expansion related to this opportunity and meeting key product delivery milestones. The agreement does not impact sales or profits in 2012 and does not include any commitments beyond 2014. While there are certain protections built into the agreement related to early termination, the extent of this project's contribution to Cambrex is contingent upon our customer's Phase 3 program not being terminated or meaningfully reduced for any reason.  Full Article

Cambrex Corporation Raises FY 2012 Guidance
Wednesday, 1 Aug 2012 04:07pm EDT 

Cambrex Corporation announced that for fiscal 2012 it expects sales, excluding the impact of foreign currency, will increase between 10% and 13% versus 2011, and that fiscal 2012 EBITDA will be between $54 and $58 million. EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities. The guidance does not reflect Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results. Cambrex's income statement reflects 51% of Zenara's net results within Equity in Losses of Partially-Owned Affiliates. For fiscal 2012, the Company continues to expect Zenara to have revenues in the low single digit millions and a small EBITDA loss. The Company reported revenue of $256 million in fiscal 2011. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $270 million and EPS of $0.70 for fiscal 2012.  Full Article

Cambrex Corporation Reaffirms FY 2012 Guidance
Thursday, 3 May 2012 04:06pm EDT 

Cambrex Corporation announced that for fiscal 2012, it expects sales, excluding the impact of foreign currency, will increase between 2%-6% versus fiscal 2011, and EBITDA, defined as operating profit plus depreciation and amortization expense, will be between $47-$53 million. The Company reported revenue of $256 million for fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $264 million and EBITDA of $51 million for fiscal 2012.  Full Article

Cambrex Corporation Comments On FY 2012 Revenue Guidance; Issues FY 2012 EBITDA Guidance In Line With Analysts' Estimates
Monday, 6 Feb 2012 04:24pm EST 

Cambrex Corporation announced that it expects fiscal 2012 sales, excluding the impact of foreign currency, will increase between 2% and 6% versus fiscal 2011, and EBITDA, defined as operating profit plus depreciation and amortization expense, will be between $47 and $53 million. EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities. The above guidance does not reflect Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $263 million and EBITDA of $50 million for fiscal 2012.  Full Article

Cambrex Corporation Issues Q4 2011 Revenue Guidance Below Analysts' Estimates-Conference Call
Friday, 4 Nov 2011 12:30pm EDT 

Cambrex Corporation announced that for the fourth quarter of 2011, it expects sales to be flat to slightly improved compared to fourth quarter of 2010. The Company reported revenues of $9.69 million in the fourth quarter of 2010. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $11.61 million for the fourth quarter of 2011.  Full Article

Search Stocks